Savara Stock Forecast
NASDAQ: SVRAHealth CareBiotechnology: Pharmaceutical PreparationsUSD
Market open · Delayed 15 min · as of Oct 9, 2:05 PM ET
SVRA analyst consensus
Consensus (9 analysts)
none
Avg. price target
$11.06+124.57%
- Strong buy 3
- Buy 6
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 9 Wall Street analysts covering Savara (2026-10-08), 9 rate the stock a buy or strong buy, 0 rate it a hold and 0 rate it a sell or strong sell, for a consensus rating of "none". The average 12-month price target is $11.06, with a high estimate of $16.00 and a low estimate of $9.00. The average target implies upside of 124.6% from the current price of $4.93.
The spread between the highest and lowest targets is 77.8%, a relatively narrow range. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for SVRA.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 3 | 33% |
| Buy | 6 | 67% |
| Hold | 0 | 0% |
| Sell | 0 | 0% |
| Strong sell | 0 | 0% |
Ratings as of 2026-10-08.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $9.00 | +82.74% |
| Average target | $11.06 | +124.57% |
| High target | $16.00 | +224.87% |